Advanced search
Publication Cover
Epigenomics Volume 3, 2011 - Issue 2
Submit an article Journal homepage
174
Views
0
CrossRef citations to date
0
Altmetric
Review

Histone Methylation in Myelodysplastic Syndromes

Yue Wei1 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX77030, USACorrespondence[email protected]
View further author information
,
Irene Gañán-Gómez1 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA;2 Department of Biochemistry & Molecular Biology, University of Alcalá;, 28871Alcalá de Henares, Madrid, Spain.View further author information
,
Sophie Salazar-Dimicoli1 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX77030, USAView further author information
,
Sara L McCay1 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX77030, USAView further author information
&
Guillermo Garcia-Manero1 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX77030, USAView further author information
Pages 193-205 | Published online: 20 Apr 2011

Bibliography

  • Nimer SD : Myelodysplastic syndromes.Blood111 , 4841–4851 (2008).
  • Rollison DE , HowladerN, SmithMTet al.: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs.Blood112 , 45–52 (2008).
  • Godley LA , LarsonRA: Therapy-related myeloid leukemia.Semin. Oncol.35 , 418–429 (2008).
  • Tefferi A , ThieleJ, VardimanW: Response: The 2008 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: a paradigm of effective collaboration among clinicians, pathologists, and scientists.Blood111 , 1742 (2008).
  • Greenberg P , CoxC, LeBeauMMet al.: International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood89 , 2079–2088 (1997).
  • Garcia-Manero G , ShanJ, FaderlSet al.: A prognostic score for patients with lower risk myelodysplastic syndrome.Leukemia22 , 538–543 (2008).
  • Dayyani F , ConleyAP, StromSSet al.: Cause of death of patients with lower risk myelodysplastic syndrome.Cancer116 , 2174–2179 (2010).
  • Haase D , GermingU, SchanzJet al.: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.Blood110 , 4385–4395 (2007).
  • Bejar R , LevineR, EbertBL: Unraveling the molecular pathophysiology of myelodysplastic syndromes.J. Clin. Oncol.29 , 504–515 (2011).
  • Issa JP : Epigenetic changes in the myelodysplastic syndromes.Hematol. Oncol. Clin. North Am.24 , 317–330 (2010).
  • Riddihough G , ZahnLM: Epigenetics. What is epigenetics? Introduction.Science330 , 611 (2010).
  • Swami M : Epigenetics: Demethylation links cell fate and cancer.Nat. Rev. Cancer10 , 740 (2010).
  • Kaiser J : Genes link epigenetics and cancer.Science330 , 577 (2010).
  • Garcia-Manero G : Progress in myelodysplastic syndromes.Clin. Lymphoma Myeloma9 , S286–S292 (2009).
  • Kuendgen A , LübbertM: Current status of epigenetic treatment in myelodysplastic syndromes.Ann. Hematol.87 , 601–611 (2008).
  • Figueroa ME , SkrabanekL, LiY, et al.: MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood114 , 3448–3458 (2009).
  • Länger F , DingemannJ, KreipeH, LehmannU: Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome.Leuk. Res.29 , 325–329 (2005).
  • Smith AE , MohamedaliAM, KulasekararajAet al: Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood116 , 3923–3932 (2010).
  • Ko M , HuangY, JankowskaAMet al.: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.Nature468(7325) , 839–843 (2010).
  • Fenaux P , MuftiGJ, Hellstrom-LindbergEet al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, Phase III study.Lancet Oncol.10 , 223–232 (2009).
  • Garcia-Manero G , YangH, Bueso-RamosCet al.: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.Blood111 , 1060–1066 (2008).
  • Garcia-Manero G , AssoulineS, CortesJet al.: Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Blood112 , 981–989 (2008).
  • Klimek VM , FircanisS, MaslakPet al.: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.Clin. Cancer Res.14 , 826–832 (2008).
  • Giles F , FischerT, CortesJet al.: A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.Clin. Cancer Res.12 , 4628–4635 (2006).
  • Klose RJ , ZhangY: Regulation of histone methylation by demethylimination and demethylation.Nat. Rev. Mol. Cell Biol.8 , 307–318 (2007).
  • Kouzarides T : Chromatin Modifications and their function.Cell128 , 693–705 (2007).
  • Lan F , NottkeAC, ShiY: Mechanisms involved in the regulation of histone lysine demethylases.Curr. Opin. Cell Biol.20 , 316–325 (2008).
  • Bedford MT : Arginine methylation at a glance.J. Cell Sci.120 , 4243–4246 (2007).
  • Martin C , ZhangY: The diverse functions of histone lysine methylation.Nat. Rev. Mol. Cell Biol.6 , 838–849. (2005).
  • Albert M , HelinK: Histone methyltransferases in cancer.Sem. Cell Develop. Biol.21 , 209–220 (2010).
  • Flanagan JF , MiLZ, ChruszczM: Double chromodomains cooperate to recognize the methylated histone H3 tail.Nature438 , 1090–1091 (2005).
  • Spektor TM , RiceJC: Identification and characterization of posttranslational modification-specific binding proteins in vivo by mammalian tethered catalysis.Proc. Natl Acad. Sci. USA106 , 14808–14813 (2009).
  • Li H , FischleW, WangWet al.: Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger.Mol. Cell28 , 677–691 (2007).
  • Shi X , HongT, WalterKLet al.: ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression.Nature442 , 96–99 (2006).
  • Barski A , CuddapahS, CuiKet al.: High-resolution profiling of histone methylations in the human genome.Cell129 , 823–837 (2007).
  • Shi Y , LanF, MatsonCet al.: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.Cell119 , 941–953 (2004).
  • Tsukada Y , FangJ, Erdjument-BromageHet al.: Histone demethylation by a family of JmjC domain-containing proteins.Nature439 , 811–816 (2006).
  • Krivtsov AV , ArmstrongSA: MLL translocations, histone modifications and leukaemia stem-cell development.Nat. Rev. Cancer7 , 823–833 (2007).
  • Okada Y , FengQ, LinYet al.: hDOT1L links histone methylation to leukemogenesis.Cell121 , 167–178 (2005).
  • Nikoloski G , LangemeijerSM, KuiperRPet al.: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.Nat. Genet.42 , 665–667 (2010).
  • Jankowska A , MakishimaH, TiuRV et al.: Mutational spectrum in chronic myelomonocytic leukemia includes genes associated with epigenetic regulation such as UTX and EZH2. Presented at: 52nd American Society of Hematology Annual Meeting and Exposition. Orlando, FL, USA, 4–7 December 2010.
  • Szpurka H , Jankowska,AM, PrzychodzenBet al.: UTX mutations and epigenetic changes in MDS/MPN and related myeloid malignancies. Presented at: 52nd American Society of Hematology Annual Meeting and Exposition. Orlando, FL, USA, 4–7 December 2010.
  • Wei Y , ChenR, Bueso-RamosCet al.: Genome-wide CHIP-Seq analysis of histone methylation reveals modulators of NF-κB signaling and the histone demethylase JMJD3 as implicated in disease progression in myelodysplastic syndrome (MDS). Presented at: 51st American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, 4–7 December 2009.
  • Milne TA , BriggsSD, BrockHWet al.: MLL targets SET domain methyltransferase activity to Hox gene promoters.Mol. Cell10 , 1107–1117 (2002).
  • Malik S and Bhaumik SR: Mixed lineage leukemia: histone H3 Lysine 4 methyltrasferases from yeast to human. FEBS J.277 , 1805–1821 (2010).
  • Dicker F , HaferlachC, SundermannJet al.: Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.Leukemia24 , 1528–1532. (2010).
  • Wang SA , JabbarK, LuGet al.: Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.Leukemia24 , 740–747 (2010).
  • Krivtsov AV and Armstrong SA: MLL translocations, histone modifications and leukeamia stem cell development. Nat. Rev. Cancer7 , 823–833 (2007).
  • Heinrichs S , BermanJN, OrtizTMet al.: CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.Br. J. Haematol.130 , 83–86 (2005).
  • Lee MG , WynderC, CoochN, ShiekhattarR: An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation.Nature437 , 432–435 (2005).
  • Saleque S , KimJ, RookeHM, OrkinSH: Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1.Mol. Cell27 , 562–572 (2007).
  • Hu X , LiX, ValverdeK, FuX, NoguchiC, QiuY, HuangS: LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.Proc. Natl Acad. Sci. USA106 , 10141–10146 (2009).
  • Huh HJ , ChaeSL, LeeM, HongKS, MunYC, SeongCMet al.: PU.1 and GFI1 mRNA expression in myelodysplastic syndrome.Int. J. Lab. Hematol.31 , 344–351 (2009).
  • Rujkijyanont P , BeyeneJ, WeiK, KhanF, DrorY: Leukaemia-related gene expression in bone marrow cells from patients with the preleukaemic disorder Shwachman–Diamond syndrome.Br. J. Haematol.137 , 537–544 (2007).
  • Lee SW , ChoYS, NaJMet al.: ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1.J. Biol. Chem.285 , 18–29 (2010)
  • Gelsi-Boyer V , TrouplinV, RoquainJet al.: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.Br. J. Haematol.151 , 365–375 (2010).
  • Gelsi-Boyer V , TrouplinV, AdélaïdeJet al.: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.Br. J. Haematol.145 , 788–800 (2009).
  • Boultwood J , PerryJ, PellagattiAet al.: Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.Leukemia24 , 1062–1065 (2010).
  • La Starza R , GorelloP, RosatiRet al.: Cryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts.Genes Chromosomes Cancer41 , 395–399 (2004).
  • Taketani T , TakiT, NakamuraH, TaniwakiM, MasudaJ, HayashiY: NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes.Cancer Genet. Cytogenet.190 , 108–112 (2009).
  • Wang GG , CaiL, PasillasMP, KampsMP: NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.Nat. Cell Biol.9 , 804–812 (2007).
  • He J , KallinEM, TsukadaY, ZhangY: The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).Nat. Struct. Mol. Biol.15 , 1169–1175 (2008).
  • Gearhart MD , CorcoranCM, WamstadJA, BardwellVJ: Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets.Mol. Cell Biol.26 , 6880–6889 (2006).
  • Martínez-Ramírez A , UriosteM, MelchorLet al.: Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array.Genes Chromosomes Cancer42 , 287–298 (2005).
  • Vakoc CR , SachdevaMM, WangH, BlobelGA: Profile of histone lysine methylation across transcribed mammalian chromatin.Mol. Cell Biol.26 , 9185–9195 (2006).
  • Feng Q , WangH, NgHHet al.: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.Curr. Biol.12 , 1052–1058 (2002).
  • Janzen CJ , HakeSB, LowellJE, CrossGA: Selective di- or trimethylation of histone H3 lysine 79 by two DOT1 homologs is important for cell cycle regulation in Trypanosoma brucei.Mol. Cell23 , 497–507 (2006).
  • Krivtsov AV , FengZ, LemieuxMEet al.: H3K79 methylation profiles define murine and human MLL-AF4 leukemias.Cancer Cell14 , 355–368 (2008).
  • Barry ER , CorryGN, RasmussenTP: Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.Expert Opin. Ther. Targets14 , 405–418 (2010).
  • Zhu YL , ZhangY, ZhuP, YangY, DuJW, LiuJ: Role of molecular screening for common fusion genes in the diagnosis and classification of leukemia.Beijing Da Xue Xue Bao.37 , 236–239 (2005).
  • Feng Y , YangY, OrtegaMMet al.: Early mammalian erythropoiesis requires the Dot1L methyltransferase.Blood116 , 4483–4491 (2010).
  • Chou ST , KhandrosE, BaileyLCet al.: Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate.Blood114 , 983–994 (2009).
  • Lahortiga I , VázquezI, AgirreXet al.: Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.Genes Chromosomes Cancer40 , 179–189 (2004).
  • Laricchia-Robbio L , PremanandK, RinaldiCR, NuciforaG: EVI1 Impairs myelopoiesis by deregulation of PU.1 function.Cancer Res.69 , 1633–1642 (2009).
  • Nishikata I , SasakiH, IgaMet al.: A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is G-CSF–induced myeloid differentiation expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation.Blood102 , 3323–3332 (2003).
  • Azuara V , PerryP, SauerSet al.: Chromatin signatures of pluripotent cell lines.Nat. Cell Biol.8 , 532–538 (2006).
  • J⊘rgensen HF , GiadrossiS, CasanovaM: Stem cells primed for action: polycomb repressive complexes restrain the expression of lineage-specific regulators in embryonic stem cells cell cycle.Cell Cycle5 , 1411–1414 (2006).
  • Mazzarella L , J⊘rgensenHF, Soza-RiedJet al.: Embryonic stem cell–derived hemangioblasts remain epigenetically plastic and require PRC1 to prevent neural gene expression.Blood117 , 83–87 (2011).
  • Paul TA , BiesJ, SmallD, WolffL: Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.Blood115 , 3098–3108 (2010).
  • Uchida T , KinoshitaT, NagaiHet al.: Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.Blood90 , 1403–1409 (1997).
  • Quesnel B , FenauxP: P15INK4b gene methylation and myelodysplastic syndromes.Leuk. Lymphoma35 , 437–443 (1999).
  • Look AT : Molecular pathogenesis of MDS.Hematology Am. Soc. Hematol. Educ. Program.156–160 (2005).
  • Liu TX , BeckerMW, JelinekJet al.: Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation. 13 , 78–83 (2007)
  • Ye Y , McDevittMA, GuoMet al.: Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.Cancer Res.69 , 8482–8490 (2009).
  • Czermin B , MelfiR, McCabeD, SeitzV, ImhofA, PirrottaV: Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites.Cell11 , 185–196 (2002).
  • Haase D , GermingU, SchanzJet al.: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.Blood110 , 4385–4395 (2007).
  • Xu F , LiX, WuL, ZhangQet al.: Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.Ann. Hematol. (2010) (Epub ahead of print).
  • Chang CJ , YangJY, XiaWet al.: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.Cancer Cell19 , 86–100 (2011).
  • Smith ER , LeeMG, WinterBet al.: Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form of RNA polymerase II.Mol. Cell Biol.28 , 1041–1046 (2008).
  • Agger K , CloosPA, ChristensenJet al.: UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development.Nature449 , 731–734 (2007).
  • Agherbi H , Gaussmann-WengerA, VerthuyC, Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS One4 , e5622 (2009).
  • Wang YY , CenJN, HeJet al.: Accelerated cellular senescence in myelodysplastic syndrome.Exp. Hematol.37 , 1310–1317 (2009).
  • Rodrigues EF , Santos-RebouçasCB, Gonçalves Pimentel MM et al.: Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. Leuk. Lymphoma51 , 1887–1894 (2010).
  • Tachibana M , MatsumuraY, FukudaM, KimuraH, ShinkaiY: G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.EMBO J.27 , 2681–2690 (2008).
  • Voutsadakis IA , MaillardN: Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature.Am. J. Hematol.72 , 135–137 (2003).
  • Wieser R : The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.Gene396 , 346–357 (2007).
  • Spensberger D , DelwelR: A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.FEBS Lett.582 , 2761–2767 (2008).
  • Lakshmikuttyamma A , ScottSA, DeCoteauJF, GeyerCR: Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.Oncogene29 , 576–588 (2010)2.
  • Aggerholm A , HolmMS, GuldbergP, OlesenLH, HoklandP: Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.Eur. J. Haematol.76 , 23–32 (2006).
  • Grövdal M , KhanR, AggerholmAet al.: Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.Clin. Cancer Res.13 , 7107–7112 (2007).
  • Botuyan MV , LeeJ, WardIMet al.: Structural basis for the methylation state-specific recognition of histone H4–K20 by 53BP1 and Crb2 in DNA repair.Cell127 , 1361–1373 (2006).
  • Schotta G , LachnerM, SarmaKet al.: A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin.Genes Dev.18 , 1251–1262 (2004).
  • Fang J , FengQ, KetelCSet al.: Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase.Curr. Biol.12 , 1086–1099 (2002).
  • Liu W , TanasaB, TyurinaOVet al.: PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression.Nature466 , 508–512 (2010).
  • Feng W , YonezawaM, YeJ, JenuweinT, GrummtI: PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation.Nat. Struct. Mol. Biol.17 , 445–450 (2010).
  • Wu MY , TsaiTF, BeaudetAL: Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain.Genes Dev.20 , 2859–2870 (2006).
  • Pal S , SifS: Interplay between chromatin remodelers and protein arginine methyltransferases.J. Cell Physiol.213 , 306–315 (2007).
  • Cheung N , ChanLC, ThompsonA, ClearyML, SoCW: Protein arginine-methyltransferase-dependent oncogenesis.Nat. Cell Biol.9 , 1208–1215 (2007).
  • Guccione E , BassiC, CasadioFet al.: Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive.Nature449 , 933–937 (2007).
  • Hyllus D , SteinC, SchnabelKet al.: PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation.Genes Dev.21 , 3369–3380 (2007).
  • Zhao X , JankovicV, GuralAet al.: Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.Genes Dev.22 , 640–653 (2008).
  • Chang B , ChenY, ZhaoY, BruickRK: JMJD6 is a histone arginine demethylase.Science318 , 444–47 (2007).
  • Loenen WA : S-adenosylmethionine: jack of all trades and master of everything?.Biochem. Soc. Trans.34 , 330–333 (2006).
  • Tan J , YangX, ZhuangLet al.: Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev.21 , 1050–1063 (2007).
  • Fiskus W , WangY, SreekumarAet al.: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.Blood114 , 2733–2743 (2009).
  • Kleer CG , CaoQ, VaramballySet al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.Proc. Natl Acad. Sci. USA100 , 11606–11611 (2003).
  • Lakshmikuttyamma A , ScottSA, DeCoteauJF, GeyerCR: Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.Oncogene29 , 576–588 (2010).
  • Kubicek S , O‘SullivanRJ, AugustEMet al.: Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.Mol. Cell25 , 473–481 (2007).
  • Castellano S , MiliteC, RagnoRet al.: Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1).Chem. Med. Chem.5 , 398–414 (2010).
  • Spannhoff A , MachmurR, HeinkeRet al.: A novel arginine methyltransferase inhibitor with cellular activity.Bioorg. Med. Chem. Lett.17 , 4150–4153 (2007).
  • Coward WR , WattsK, Feghali-BostwickCA, JenkinsG, PangL: Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.Mol. Cell Biol.30 , 2874–2886 (2010).
  • Spannhoff A , HauserAT, HeinkeR, SipplW, JungM: The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.Chem. Med. Chem.4 , 1568–1582 (2009).
  • Binda C , ValenteS, RomanenghiMet al.: Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.J. Am. Chem. Soc.132 , 6827–6833 (2010).
  • Mackeen MM , KramerHB, ChangKHet al.: Small-molecule-based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry.J. Proteome Res.9 , 4082–4092 (2010).
  • Hamada S , SuzukiT, MinoKet al.: Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.J. Med. Chem.53 , 5629–5638 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.